Monte Rosa Therapeutics

Monte Rosa Therapeutics Stock-Based Compensation

The Stock-Based Compensation (SBC) of Monte Rosa Therapeutics (GLUE) as of Oct 17, 2026 is 18.87 M USD. In the previous year, Stock-Based Compensation (SBC) was 18.13 M USD — a change of 4.08% (higher).

Stock-Based Compensation

18.87 MUSD

YoY

4.08%

Last updated:

Stock-Based Compensation (SBC) of Monte Rosa Therapeutics is 2025 18.87 M USD. Stock-Based Compensation (SBC) of Monte Rosa Therapeutics was 2024 18.13 M USD. It decreases by 4.08% higher compared to the previous year.

The Monte Rosa Therapeutics Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2019
0.00 USD
Jan 1, 2020
354,000.00 USD
Jan 1, 2021
5.20 M USD
Jan 1, 2022
11.66 M USD
Jan 1, 2023
16.67 M USD
Jan 1, 2024
18.13 M USD
Jan 1, 2025
18.87 M USD
The Monte Rosa Therapeutics Stock-Based Compensation history
YEARStock-Based CompensationYoY
18.87 MUSD+4.08%
18.13 MUSD+8.74%
16.67 MUSD+42.91%
11.66 MUSD+124.31%
5.20 MUSD+1,368.93%
354,000.00USD—
0.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Monte Rosa Therapeutics Stock analysis

What does Monte Rosa Therapeutics do? Monte Rosa Therapeutics Inc, headquartered in Boston, Massachusetts, operates in the Health Care sector within the Biotechnology industry. The company employs 150 full-time employees and went public on June 24, 2021. It focuses on developing precision medicines, particularly molecular glue degraders (MGDs), which selectively target proteins for degradation using the body's natural mechanisms. Monte Rosa has developed a platform called QuEEN (Quantitative and Engineered Elimination of Neosubstrates) to support its MGD discovery and development. Its lead product candidate, MRT-2359, is an orally bioavailable MGD targeting GSPT1 for potential treatment of MYC-driven tumors, including metastatic non-small cell lung cancer and small cell lung cancer. Monte Rosa Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Monte Rosa Therapeutics stock

Stock-Based Compensation (SBC) of Monte Rosa Therapeutics is 18.87 M USD in 2025.

Stock-Based Compensation (SBC) of Monte Rosa Therapeutics changed from 18.13 M USD to 18.87 M USD, representing a 4.08% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Monte Rosa Therapeutics since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Monte Rosa Therapeutics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Monte Rosa Therapeutics

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Monte Rosa Therapeutics